April 23, 2015
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Amgen first quarter beats Wall Street expectations
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
On April 22, Amgen Inc. reported first-quarter profit that beat Wall Street expectations, which the company attributed to an increase in demand, and price, for their drugs. Amgen reported that earnings per share grew 33% to $2.48. Adjusted operating income increased 32% to $2,449 million. Total revenues increased 11% to $5,033million.
First quarter 2015 product sales performance
- Neulasta(pegfilgrastim) sales increased 4% year-over-year driven primarily by price.
- NEUPOGEN (filgrastim) sales decreased 15% year-over-year driven primarily by the impact of competition in the United States.
- ENBRELsales increased 13% year-over-year driven by price.
- XGEVA sales increased 22%year-over-year driven by higher unit demand.
- Proliasales increased 39%year-over-year driven by higher unit demand.
- EPOGEN sales increased 16%year-over-year due primarily to price and, to a lesser extent, higher unit demand.
- Aranesp(darbepoetin alfa) sales increased 4% year-over-year driven by higher unit demand in international markets.
- Sensipar/Mimpara sales increased 24% year-over-year driven by higher unit demand, favorable changes in inventory levels, and price.
- Nplate (romiplostim) sales increased 12% year-over-year driven by higher unit demand.
- Vectibix(panitumumab) sales increased 18% year-over-year driven by higher unit demand.
- Kyprolis(carfilzomib) sales increased 59% year-over-year driven by higher unit demand.